Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early treatment with deferasirox in low-risk myelodysplastic syndromes
2008-006268-12Phase 2Terminated
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Friedrich-Alexander University Erlangen-Nuremberg. Primary endpoint: Hematologic improvement per modified IWG criteria. Started Jul 2009; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-006268-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006268-12.